Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17

Cancer

Volumn 117, Issue 1, 2011, Pages 48-53

  Vranic, Semir ^a,b   Teruya, Bryan ^a   Repertinger, Susan ^a   Ulmer, Pamela ^a   Hagenkord, Jill ^a   Gatalica, Zoran ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

Author keywords

amplification; breast cancer; CEP17 polysomy; fluorescent in situ hybridization; HER2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CELL NUCLEUS; CHROMOSOME 17; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE DOSAGE; HER2 GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NUMERICAL CHROMOSOME ABERRATION; POLYSOMY 17; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 17; DNA COPY NUMBER VARIATIONS; FEMALE; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, ERBB-2;

EID: 78650689078     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25580     Document Type: Article

References (29)

1. Perez EA., Cardiac toxicity of ErbB2-targeted therapies: what do we know? Clin Breast Cancer. 2008; 8 (suppl 3): S114-S120.
2. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006; 355: 2733-2743.
3. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 25: 118-145.
4. Amar S, Roy V, Perez EA., Treatment of metastatic breast cancer: looking towards the future. Breast Cancer Res Treat. 2009; 114: 413-422.
5. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-792.
6. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T., The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science. 1986; 232: 1644-1646. (Pubitemid 16095607)
7. Sauter G, Lee J, Bartlett JMS, Slamon DJ, Press MF., Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009; 27: 1323-1333.
8. Bartlett J, Going J, Mallon E, et al. Evaluating HER2 amplification and overexpresson in breast cancer. J Pathol. 2001; 195: 422-428.
9. Watters AD, Going JJ, Cooke TG, et al. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat. 2003; 77: 109-114.
10. Reinholz MM, Bruzek AK, Visscher DW, et al. Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. Lancet Oncol. 2009; 10: 267-277.
11. Vanden Bempt I, Van Loo P, Drijkoningen M, et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol. 2008; 26: 4869-4874.
12. Yeh IT, Martin MA, Robetorye RS, et al. Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol. 2009; 22: 1169-1175.
13. Wang S, Saboorian H, Frenkel EP, et al. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol. 2002; 15: 137-145.
14. Marchio C, Lambros MB, Gugliotta P, et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol. 2009; 219: 16-24.
15. Lyons-Weiler M, Hagenkord J, Sciulli CM, Dhir R, Monzon FA., Optimization of the Affymetrix GeneChip mapping 10 K 2.0 assay for routine clinical use on formalin fixed paraffin embedded tissues. Diagn Mol Pathol. 2008; 17: 3-13.
16. Monzon FA, Hagenkord J, Lyons-Weiler M, et al. Whole genome SNP arrays as a potential diagnostic tool for the detection of characteristic chromosomal aberrations in renal epithelial tumors. Mod Pathol. 2008; 21: 599-608.
17. Vranic S, Tawfik O, Palazzo J, et al. EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Mod Pathol. 2010; 23: 644-653.
18. Krishnamurti U, Hammers JL, Atem FD, Storto PD, Silverman JF., Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma. Mod Pathol. 2009; 22: 1044-1048.
19. Hyun CL, Lee HE, Kim KS, et al. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J Clin Pathol. 2008; 61: 317-321.
20. Cuadros M, Talavera P, Lopez FJ, Garcia-Perez I, Blanco A, Concha A., Real-time RT-PCR analysis for evaluating the Her2/neu status in breast cancer. Pathobiology. 2010; 77: 38-45.
21. Ma Y, Lespagnard L, Durbecq V, et al. Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res. 2005; 11: 4393-4399.
22. Varshney D, Zhou YY, Geller SA, Alsabeh R., Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol. 2004; 121: 70-77.
23. Salido M, Tusquets I, Corominas JM, et al. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. Breast Cancer Res. 2005; 7: R267-R273.
24. Merola R, Mottolese M, Orlandi G, et al. Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis. Eur J Cancer. 2006; 42: 1501-1506.
25. Zhang Y, Martens JW, Yu JX, et al. Copy number alterations that predict metastatic capability of human breast cancer. Cancer Res. 2009; 69: 3795-3801.
26. Moelans CB, de Weger RA, van Diest PJ., Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Res Treat. 2010; 120: 1-7.
27. Bartlett J, Munro A, Desmedt C, et al. Cancer duplication of chromosome 17 CEP predicts for anthracycline benefit: a meta-analysis of 4 trials [abstract]. Cancer Res. 2009; 69 (suppl 24): 716S Abstract nr 4030.
28. Bartlett J, Munro A, Dunn J, et al. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol. 2010; 11: 266-274.
29. Tubbs RR, Hicks DG, Cook J, et al. Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 status in adenocarcinoma of the breast: a single institution experience. Diagn Mol Pathol. 2007; 16: 207-210.